Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 6, 2024
Subject: Interim analysis results of the DREAMM-7 Phase III clinical trial for Blenrep (belantamab mafodotin) in the treatment of relapsed/refractory multiple myeloma.
Key Financial Metrics
This filing is a clinical trial update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing reports statistically significant improvements in the DREAMM-7 trial comparing Blenrep plus bortezomib/dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment settings.
- Progression-Free Survival (PFS): Median PFS was 36.6 months for the Blenrep combination versus 13.4 months for the daratumumab combination. This represents a 59% reduction in the risk of disease progression or death (HR: 0.41, p<0.00001).
- Overall Survival (OS): A strong trend favoring Blenrep was observed with a 43% reduction in the risk of death (HR: 0.57, p=0.00049). However, this has not yet reached the interim criteria for statistical significance.
- Response Rates: Overall Response Rate (ORR) was 82.7% for Blenrep vs. 71.3% for daratumumab. Minimal Residual Disease (MRD) negativity rate was 24.7% vs. 9.6%.
- Duration of Response: Median duration was 35.6 months for Blenrep vs. 17.8 months for daratumumab.
Outlook, Risks, and Management Commentary
Management Commentary: GSK leadership stated that the results reinforce the potential for belantamab mafodotin to redefine multiple myeloma treatment at or after first relapse. The company plans to share these results with global health authorities.
Future Outlook: The DREAMM-8 Phase III trial, evaluating Blenrep in combination with pomalidomide and dexamethasone, is ongoing with data expected in the second half of 2024.
Risks and Safety:
- Ocular Adverse Events: Grade 3 or higher ocular events occurred in 34% of patients (e.g., blurred vision, dry eye). These were generally reversible, with a median resolution time of 22 days. Treatment discontinuation due to eye-related side effects was low (9%).
- Other Adverse Events: Grade 3+ non-ocular events included thrombocytopenia (55%), neutropenia (12%), and pneumonia (12%).
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their 2022 Form 20-F and 2023 Q4 results.
Investor Verification Checklist
- Verify the regulatory submission timeline for Blenrep based on these DREAMM-7 results.
- Monitor the final Overall Survival (OS) data, as the interim analysis did not meet the pre-specified statistical significance threshold.
- Review the long-term safety profile regarding ocular adverse events in the full study population.
- Track the progress and expected data release for the DREAMM-8 trial in late 2024.
- Assess the potential impact of these results on GSK's oncology revenue projections in upcoming earnings reports.